Domestic growth to be moderated by subdued US, ICICI Direct Research

The I-direct healthcare universe (12 coverage companies) is expected to post decent YoY growth of ~7% to ~| 43930 crore led by continued chronic traction in the domestic market partly offset by a decline in US formulations amid lack of meaningful new launches and a weak flu season. Domestic growth is expected to be led by a partial recovery in the acute segment, reasonable traction in the chronic segment and Covid-related product sales. US formulations are expected to remain subdued amid lack of new launches and waning currency tailwinds from preceding quarters.

For complete report: IDirect Healthcare Q4FY21

MB Bureau